These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 7687611)

  • 1. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
    Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
    J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
    Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
    J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
    Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
    J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
    Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
    J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
    Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
    J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
    Jacobson S; Reuben JS; Streilein RD; Palker TJ
    J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
    Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
    Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
    Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of monoclonal antibodies directed against the gp46 of human T-cell leukemia virus type I.
    Edouard E; Legrand E; Astier-Gin T; Dalibart R; Geoffre S; Dalbon P; Guillemain B; Londos-Gagliardi D
    Leukemia; 1994 Apr; 8 Suppl 1():S60-4. PubMed ID: 7512182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
    Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
    Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
    Hadlock KG; Yang Q; Rowe J; Foung SK
    AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
    Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
    Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
    J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
    Hadlock KG; Rowe J; Perkins S; Bradshaw P; Song GY; Cheng C; Yang J; Gascon R; Halmos J; Rehman SM; McGrath MS; Foung SK
    J Virol; 1997 Aug; 71(8):5828-40. PubMed ID: 9223472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
    Kuo CW; Mirsaliotis A; Brighty DW
    J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
    Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
    Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
    Tanaka Y; Tanaka R; Hoshino H
    Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
    Hadlock KG; Rowe J; Foung SK
    J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
    Kaumaya PT; Conrad SF; DiGeorge AM; Lairmore MD
    Leukemia; 1995 Oct; 9 Suppl 1():S133-8. PubMed ID: 7475306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.